Reported 2 days ago
Morgan Stanley has increased its price target for Tenet Healthcare (THC) to $210 from $175 while maintaining an Overweight rating. Analyst Craig Hettenbach noted that Tenet is a preferred stock in the hospital sector, citing strong Q1 2025 revenues of $5.2 billion and a 14% rise in adjusted EBITDA year-over-year. Despite this positive performance, the company refrained from updating its full-year guidance due to uncertainties.
Source: YAHOO